In a press release Tuesday, biotechnology company Genaissance said it expects each company will contribute parts of intellectual property derived from their respective programs.Genaissance, New Haven, Conn., will receive funding to apply its HAP Technology to Bayer's clinical samples. Bayer will receive exclusive rights to develop and market diagnostic tests based on the results of that collaboration.http://biz.yahoo.com/djus/030121/0718000432_1.html
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat